Oligoribonucleotides and ribonucleases for cleaving RNA

Details Oligoribonucleotides and ribonucleases for cleaving RNA Oligoribonucleotides and ribonucleases for cleaving RNA

1997-06-06

2000-08-22

Elliott, George C.

Chemistry: molecular biology and microbiology

Process of mutation, cell fusion, or genetic modification

Introduction of a polynucleotide molecule into or...

435 6, 435 911, 435 913, 435 9131, 435440, 435375, 435377, 536 231, 536 241, 536 245, C07H 2104, C07H 2102, C12N 1500, C12Q 168

Patent

active

061070947

ABSTRACT:
Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4373071 (1983-02-01), Itakura
patent: 4401796 (1983-08-01), Itakura
patent: 4469863 (1984-09-01), Ts'o. et al.
patent: 4507433 (1985-03-01), Miller et al.
patent: 4812512 (1989-03-01), Buendia et al.
patent: 4908405 (1990-03-01), Bayer et al.
patent: 5013830 (1991-05-01), Ohtsuka et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5130302 (1992-07-01), Spielvogel et al.
patent: 5142047 (1992-08-01), Tullis
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5177198 (1993-01-01), Spielvogel et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5235033 (1993-08-01), Summerton et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264562 (1993-11-01), Matteucci
patent: 5264564 (1993-11-01), Matteucci
patent: 5359044 (1994-10-01), Cook et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5391667 (1995-02-01), Dellinger
patent: 5403711 (1995-04-01), Walder et al.
patent: 5457191 (1995-10-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5484908 (1996-01-01), Froehler et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5506351 (1996-04-01), McGee
patent: 5508270 (1996-04-01), Baxter et al.
patent: 5514786 (1996-05-01), Cook et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5614617 (1997-03-01), Cook et al.
patent: 5962425 (1999-10-01), Walder et al.
Branch A. "A Good Antisense is Hard to Find" TIBS vol. 23:45-50, Feb. 1998.
Agrawal S. "Antisense Oligonucleotides: Towards Clinical Trials" TIBTECH vol. 14:376-388, Oct. 1996.
Ausubel, et al., Eds., Current Protocols in Molecular Biology, 1988, Wiley & Sons, New York.
Beaucage S. and Iyer, R., "Advances in the synthesis of oligonucleotides by the phosphoramidite approach", Tetrahedron Letters, 1992, 48, 2223-2311.
Beaucage S. and Iyer, R., "The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications", Tetrahedron, 1993, 49, 6123-6194.
Bhat, et al., "A Simple and Convenient Method for the Selective N-Acylations of Cytosine Nucleosides", Nucleosides and Nucleotides, 1989, 8, 179-183.
Crooke, S.T. and Bennett, C.F., "Progress in Antisense Oligonucleotide Therapeutics", Annu. Rev. Pharmacol. Toxicol., 1996, 36, 107-129.
Crooke, et al., "Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes", Biochem. J., 1995, 312, 599-608.
Dagle, et al., "Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis", Nucleic Acids Research, 1990, 18, 4751-4757.
Dagle, et al., "Pathways of Degradation and Mechanism of Action of Antisense Oligonucleotides in Xenopus laevis Embryos", Antisense Res. and Dev., 1991, 1, 11-20.
Dagle, et al., "Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages", Nucleic Acids Research, 1991, 19, 1805-1810.
Englisch, U. and Gauss, D.H., "Chemically Modified Oligonucleotides as Probes and Inhibitors", Angewandt Chemie, International Edition Engl., 1991, 30, 613-629.
Haeuptle and Dobberstein, "Translation arrest by oligonucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length", Nucleic Acids Res., 1986, 14, 1427-1448.
Eder, P.S. and Walder, J.A., "Ribonuclease H from K562 Human Erythroleukemia Cells", J. Biol. Chem., 1991, 266, 6472-6479.
Kawasaki, et al., "Uniformly Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets", J. Med. Chem., 1993, 36, 831-841.
Kawasaki, et al., "Synthesis and Biophysical Studies of 2'-dRIBO-2'-F Modified Oligonucleotides", ISIS Pharmaceuticals, Inc., 2280 Faraday Avenue, Carlsbad, CA 92008, USA (1991).
Martin, "Ein neuer Zugang zu 2'-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide", Helv. Chim. Acta., 1995, 78, 486-504.
Monia, et al., "Selective Inhibition of Mutant Ha-ras mRNA Expression by Antisense Oligonucleotides", J. Biol. Chem., 1992, 267, 19954-19962.
Monia, et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression", J. Biol. Chem., 1993, 268, 14514-14522.
Reese, C.B., et al., "4-(1,2,4-Triazol-1-yl)-and 4-(3-Nitro-1,2,4-triazol-1-yl)-1-(.beta.-D-Arabinofuranosyl)cytosine(Ara-C )", J. Chem. Soc. Perkin Trans. I, 1982, pp. 1171-1176.
Robins, et al., "Nucleic acid related compounds. 41. Restricted furanose conformations of 3',5'-O(1,1,3,3-tetraisoprpyldisilox-1,3-diyl)nucleosides provide a convenient evaluation of anomeric configuration.sup.1,2 ", Can. J. Chem., 1983, 61, 1911-1920.
Saison-Behmoaras, T., et al., "Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation", EMBO, 1991, 10, 1111-1118.
Concise Encyclopedia of Polymer Science and Engineering, pp. 858-859, Kroschwitz, J.I., Ed., John Wiley & Sons, 1990.
Oligonucleotide Synthesis, A Practical Approach, M.J. Gait, Ed., IRL Press, 1984.
Oligonucleotide and Analogs, A Practical Approach, F. Eckstein, Ed., IRL Press, 1991, Chapters 1-7.
De Mesmeker, et al., "Antisense Oligonucleotides", Acc. Chem. Res., 1995, 28, 366-374.
Goodchild, et al., "Conjugates of Oligonucleotides and Modified Oligonucleotides: A Review of their Synthesis and Properties", Bioconjugate Chem., 1990, 1(3), 165-187.
Menelev, et al., Bioorg. & Med. Chem. Lett., 1994, 4(24), 2929-2934.
Lengyel, J. Enzym. Res., 1987, 7, 511-519.
Milligan, J. Med. Chem., 1993, 36, 1923.
Tseng, et al., "Antisense Oligonucleotide Technology in the Development of Cancer Therapeutics", Cancer Gene Therapeutics, 1994, 1, 65-71.
Westermann, et al., "Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides", Biomed. B. Acta., 1989, 48, 85-93.
Stein, C.A. et al., "Antisense Oligonucleotides as Therapeutic Agents--Is the Bullet Really Magical?", Science, 1993, 261, 1004-1012.
Stull, et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", Pharm. Res., 1995, Pharm. Rev., 12, 465-482.
Uhlmann, et al., "Antisense Oligonucleotides: A New Therapeutic Principle", Chem. Rev., 1990, 90, 543.
Sands, et al., "Biodistribution and Metabolism of Internally .sup.3 H-Labeled Olionucleotides. II. 3',5'-Blocked Oligonucleotides", Am. Soc. Pharmacol. Exp. Ther., 1995, 47, 636-646.
Strickland, et al., "Antisense RNA Directed Against the 3' Noncoding Region Prevents Dormant mRNA Activation in Mouse Oocytes", Science, 1988, 241, 680-684.
Akashi, et al., "Novel Stationary Phases for Affinity Chromatography. Nucleobase-Selective Recognition of Nucleosides and Nucleotides on

Affiliated with

Also associated with

Rating

Oligoribonucleotides and ribonucleases for cleaving RNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligoribonucleotides and ribonucleases for cleaving RNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligoribonucleotides and ribonucleases for cleaving RNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-579541